The Department of Health and Human Services is the Federal government's principal agency for protecting the health of all Americans and providing essential human services, especially to those who are least able to help themselves.
|Recipient||Amount||Start Date||End Date|
|Plug & Play, Llc||$ 200,000||   ||2019-09-01||2024-08-31|
|University Enterprise Laboratories, Inc.||$ 200,000||   ||2019-09-01||2024-08-31|
|University Of Missouri System||$ 193,412||   ||2019-09-01||2024-08-31|
|Emory University||$ 199,872||   ||2019-09-01||2024-08-30|
|Life Science Washington Institute||$ 299,946||   ||2018-06-01||2023-05-31|
|New Orleans Bioinnovation Center, Inc.||$ 257,347||   ||2018-06-01||2023-05-31|
|Texas Medical Center||$ 289,500||   ||2018-06-01||2023-05-31|
|Medtech Innovator||$ 300,000||   ||2018-06-01||2023-05-31|
|First Flight Venture Center, Inc.||$ 295,740||   ||2018-06-01||2023-05-31|
|University Of Massachusetts||$ 299,998||   ||2018-06-01||2023-05-31|
Fiscal Year 2009: No Current Data Available Fiscal Year 2010: It is anticipated that 20 applications will be received and 12 awards will be issued in fiscal year 2010. Fiscal Year 2011: No Current Data Available
Uses and Use Restrictions
Support international in-country advanced development and industrialization of human pandemic influenza vaccine.
Support activities related to the mitigation of the global shortage of influenza vaccines through awards and sub-awards to developing countries with the potential and capacity to manufacture various influenza vaccines.
Basic research (e.g.
scientific or medical experiments) is not allowable.
100% of funds are for discretionary activities.
All types of entities are eligible, including highly qualified foreign nationals outside the United States either alone or in collaboration with American participants when such transactions may inure to the benefit of the American people.
Applicants should review the individual funding opportunity announcements issued under this CFDA program.
All individuals including at-risk individuals such as children, pregnant women, elderly, and others at-risk who may be given special priority.
Applicants should review the individual funding opportunity announcements issued under this CFDA program for any credentials or certifications that must be submitted prior to or simultaneous with submission of an application package. OMB Circular No. A-87 applies to this program.
Aplication and Award Process
Preapplication coordination is not applicable.
Environmental impact information is not required for this program.